63 / 74
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 5, September/October 2017
AFRICA
337
47. Lockhat FB, Emembolu JO, Konje JC. The evaluation of iron status in
hemodialysis patients.
Hum Reprod
2004;
19
: 179–184.
48. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V,
et
al.
The role of iron status markers in predicting response to intravenous
iron in haemodialysis patients on maintenance erythropoietin.
Nephrol
Dial Transplant
2001;
16
: 1416–1423.
49. Kalantar-Zadeh K, Rodriguez R., Humphreys MH. Association
between serum ferritin and measures of inflammation, nutrition and
iron in haemodialysis patients.
Nephrol Dial Transplant
2004;
19
:
141–149.
50. Okonko D, Grzeslo A, Witkowski T, Mandal A, Slater R, Roughton M,
et al.
Effect of intravenous iron sucrose on exercise tolerance in anemic
and nonanemic patients with symptomatic chronic heart failure and iron
deficiency.
J Am Coll Cardiol
2008;
51
: 103–112.
51. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian
R,
et al.
Intravenous iron alone for the treatment of anemia in patients
with chronic heart failure.
J Am Coll Cardiol
2006;
48
: 1225–1227.
52. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron
without erythropoietin for the treatment of iron deficiency anemia in
patients with moderate to severe congestive heart failure and chronic
kidney insufficiency.
J Nephrol
2008;
21
: 236–242.
53. Reed BN, Blair E, Thudium EM, Waters SB, Sueta C, Jensen BC,
et
al.
Effects of an accelerated intravenous iron regimen in hospitalized
patients with advanced heart failure and iron deficiency.
Pharmacother
J Hum Pharmacol Drug Ther
2015;
35
: 64–71.
54. Ben-Assa E, Shacham Y, Shashar M, Leshem-rubinow E, Gal-oz A,
Schwartz IF,
et al.
Target hemoglobin may be achieved with intravenous
iron alone in anemic patients with cardiorenal syndrome: An observa-
tional study.
Cardiorenal Med
2015;
64239
: 246–253.
55. Gaber R, Kotb N., Ghazy M, Nagy HM, Salama M, Elhendy A,
et al.
Tissue Doppler and strain rate imaging detect improvement of myocar-
dial function in iron deficient patients with congestive heart failure after
Iron replacement therapy.
Echocardiography
2012;
29
: 13–18.
56. Bolger AP, Bartlett FR, Penston HS, Leary JO,
et al.
Intravenous iron
alone for the treatment of anemia in patients with chronic heart failure.
J Am Coll Cardiol
2006;
48
: 1225–1227.
57. Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic param-
eters in iron deficiency patients with heart failure and chronic kidney
disease treated with intravenous iron.
Hear Lung Circ
2015;
24
: 686–695.
58. Terrovitis JV, Kaldara E, Ntalianis A, Sventzouri S, Kapelios C,
Barbarousi D,
et al.
Intravenous iron alone is equally effective with
the combination of iron and erythropoietin for the treatment of iron-
deficiency anemia in advanced heart failure.
J Am Coll Cardiol
2012;
60
: 2255–2256.
59. Drakos SG, Anastasiou-Nana MI, Malliaras KG, Nanas JN. Anemia in
chronic heart failure.
Congest Heart Fail
2009;
15
: 87–92.
60. Arutyunov G, Bylova N, Ivleva A, Kobalava Z. The safety of intrave-
nous (IV) ferric carboxymaltose versus IV iron sucrose on patients with
chronic heart failure (CHF) and chronic kidney disease (CKD) with iron
deficincy (ID).
Eur J Heart Fail
2009;
8
: ii71.
61. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron
reduces NT-pro-brain natriuretic peptide in anemic patients with
chronic heart failure and renal insufficiency.
J Am Coll Cardiol
2007;
50
: 1657–1665.
62. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de
Albuquerque D,
et al.
IRON-HF study: a randomized trial to assess the
effects of iron in heart failure patients with anemia.
Int J Cardiol
2013;
168
: 3439–3442.
63. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, Wasserman
SM, Baker N,
et al.
Randomized, double-blind, placebo-controlled
study to evaluate the effect of two dosing regimens of darbepoetin
alfa in patients with heart failure and anaemia.
Eur Heart J
2007;
28
:
2208–2216.
64. Niehaus ED, Malhotra R, Cocca-Spofford D, Semigran M, Lewis GD.
Repletion of iron stores with the use of oral iron supplementation in
patients with systolic heart failure.
J Card Fail
2015;
21
: 694–697.
65. Tay ELW, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez
R, Giannakoulas G,
et al.
Replacement therapy for iron deficiency
improves exercise capacity and quality of life in patients with cyanotic
congenital heart disease and/or the Eisenmenger syndrome.
Int J Cardiol
2011;
151
: 307–312.
66. Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis
I,
et al.
Effects of darbepoetin
α
on right and left ventricular systolic and
diastolic function in anemic patients with chronic heart failure second-
ary to ischemic or idiopathic dilated cardiomyopathy.
Am Heart J
2008;
155
: 1–7.
67. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G,
Calabrò A,
et al.
Erythropoietin improves anemia exercise tolerance and
renal function and reduces B-type natriuretic peptide and hospitaliza-
tion in patients with heart failure and anemia.
Am Heart J
2006;
152
:
1096 e9–15.
68. Makubi A, Lwakatare J, Mmbando PM, Camilla CH, Mtali Y, Janabi
M, Kisenge P, Rydén L, Makani J LL. Oral iron improves serum
ferritin in patients with heart failure and iron deficiency: A prospective
single-arm trial within the Tanzania heart failure study (TaHeF-ID). In
submisssion
Heart
2017.
69. Lewis GD, Semigran MJ, Givertz MM, Malhotra R, Anstrom KJ,
Hernandez AF,
et al.
Oral iron therapy for heart failure with reduced
ejection fraction design and rationale for oral iron repletion effects on
oxygen uptake in heart failure.
Circ Hear Fail
2016;
9
: e000345.